Susquehanna International Group’s Aprea Therapeutics APRE Stock Holding History

Susquehanna International Group’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-104,300	Closed	-$490K	–	12107
2023 Q4	$490K	Hold	104,300	–	–	﹤0.01%	8712
2023 Q3	$437K	Hold	104,300	–	–	﹤0.01%	8550
2023 Q2	$329K	Sell	104,300 -6,000	-5%	-$22.4K	﹤0.01%	9260
2023 Q1	$491K	Buy	110,300 +103,070	+1,426%	+$761K	﹤0.01%	8615
2022 Q4	$46.3K	Hold	7,230	–	–	﹤0.01%	11438
2022 Q3	$94K	Buy	7,230 +745	+11%	+$13.2K	﹤0.01%	11747
2022 Q2	$96K	Buy	6,485 +225	+4%	+$5.19K	﹤0.01%	11521
2022 Q1	$233K	Buy	6,260 +5,090	+435%	+$209K	﹤0.01%	10865
2021 Q4	$67K	Buy	+1,170	New	+$103K	﹤0.01%	12401
2021 Q3	–	Sell	-2,145	Closed	-$209K	–	12691
2021 Q2	$209K	Buy	2,145 +1,090	+103%	+$101K	﹤0.01%	11510
2021 Q1	$108K	Buy	+1,055	New	+$123K	﹤0.01%	11819

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's APRE Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Aprea Therapeutics (APRE) in Q1 2026: 13,018 shares worth $9.93K. The stake represents ﹤0.01% of the portfolio and ranks #12940 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in APRE as recently as Q2 2024.

Susquehanna International Group first reported a position in APRE in Q2 2021 and has held it in 9 quarters since. The position peaked at $1.02M in Q3 2021. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

Susquehanna International Group held 13,018 shares of Aprea Therapeutics worth $9.93K as of Q1 2026.
Aprea Therapeutics was a new Susquehanna International Group position in Q1 2026.
Aprea Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12940 holding.
Susquehanna International Group first reported a position in Aprea Therapeutics in Q2 2021 and has held it in 9 quarters since.
Susquehanna International Group's Aprea Therapeutics position peaked at $1.02M in Q3 2021.
22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.